Molecular Profiling for Cancers of Unknown Primary Origin

Policy Number: AHS – M2065 – Molecular Profiling for Cancers of Unknown Primary Origin
Initial Presentation Date: 1/01/2020
Revision Date: 8/01/2020

Policy Description

Cancers of unknown primary origin (CUPs) are defined as the 4-5 percent of invasive cancers for which no primary site can be identified despite an extensive diagnostic work-up (Fizazi et al., 2015; Varadhachary & Raber, 2014). CUPs are generally considered to represent metastases and are associated with a very poor prognosis (Vikeså et al., 2015).

Gene expression assays measure the amount of specific mRNAs being transcribed to assess the genes that are active in a particular cell or tissue. Analyses of gene expression can be clinically useful for disease classification, diagnosis, prognosis, and tailoring treatment to underlying genetic determinants of pharmacologic response (Steiling, 2019).

Related Policies

<table>
<thead>
<tr>
<th>Policy Number</th>
<th>Policy Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>AHS-M2066</td>
<td>Genetic Cancer Susceptibility Using Next Generation Sequencing</td>
</tr>
</tbody>
</table>

Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request.

*The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of a patient’s illness.*

1. Molecular cancer classifier and/or gene expression profiling assays are **EXPERIMENTAL AND INVESTIGATIONAL** to evaluate the site of origin of a tumor of unknown primary, or to distinguish a primary from a metastatic tumor, or to guide site-specific therapy.

2. Mutational testing with next generation sequencing are **EXPERIMENTAL AND INVESTIGATIONAL** to determine targeted treatments for patients diagnosed with cancer of unknown primary origin.

Scientific Background

Cancers of unknown primary origin (CUPs) typically present with symptoms attributable to metastases where subsequent work-up fails to identify the primary site (J. Hainsworth & Greco,
2019). Given their rapid progression and dissemination, it was assumed that regardless of the site of origin, the tumors in unknown primary cancers shared biologic properties common to their pathogenesis and that identification of the exact tissue of origin would not have a substantial effect on therapeutic approaches or survival. However, biologic events that allow development of metastases without a discernable tumor at the primary site have not yet been determined (Varadhachary & Raber, 2014).

Accurate prediction of the tissue of origin using immunohistochemical staining and/or gene expression profiling is now possible in certain CUP cases. Appropriate classification, based upon all available evidence, is essential to identify patients for whom a specific treatment may be particularly useful and site-specific therapy based on these predictions is replacing empiric chemotherapy as the new treatment standard (J. Hainsworth & Greco, 2019). Tumors in unknown primary cancer despite different degrees of loss of differentiation retain the signature of their primary origin, even after metastasis (Fizazi et al., 2015).

Presently, patients are initially placed into one of four categories (adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, poorly differentiated) based upon the light microscopic examination of the initial biopsy. This classification is then used to guide further evaluation as indicated below (F. Greco & Hainsworth, 2011):

Although the true tissue of origin may not be identifiable in any given case, recent evidence suggests it may be useful to provide “site-specific” treatment based on tumor type (J. Hainsworth & Greco, 2019). Certain characteristics of a tumor, such as its histology, may indicate more responsive cases and as such, may warrant specific treatments. For example, a woman with peritoneal carcinomatosis may benefit from therapies that are effective against advanced epithelial ovarian cancer, as the histology in both types may be similar. However, although several of these subgroups have been identified, most patients will not fall in these groups; approximately 70% of cancers of unknown primary are classified as adenocarcinomas, and 80-85% of these adenocarcinomas are not yet classified into these subgroups. In the absence of a targeted therapy, “empiric” chemotherapy with efficacy against a broad swath of
cancer types is usually provided (J. Hainsworth & Greco, 2019; J. D. Hainsworth, Greco, Anthony, 2020).

Several proprietary tests exist for the assessment of the origin of cancer. One of these tests is "Tissue of Origin” from Cancer Genetics Inc. This test is a “microarray-based gene expression that aids in identifying challenging tumors, including metastatic, poorly differentiated, and undifferentiated cancers”. This test assesses the expression level of over 2000 genes and reports the likeliest tissue of origin from the most 15 common tumor types ("breast, non-small cell lung, pancreas, gastric, colorectal, liver, bladder, kidney, thyroid, non-Hodgkin lymphoma, melanoma, ovarian, sarcoma, testicular germ cell, and prostate"). An RNA “profile” is generated from the expression levels and compared to tissue profiles representative of the 15 tumors (ClinLabNavigator, 2019). Another test is “CancerTYPE ID”, which measures the expression of 92 genes encompassing 50 tumor types. The test is intended to aid in identifying tissue of origin as well as tumor subtype. The firm that offers this test is Biotheranostics, Inc (Biotheranostics, 2019).

Tissue of Origin was validated by Pillai et al where they created microarray data files for 462 “metastatic, poorly differentiated, or undifferentiated FFPE tumor specimens, all of which had a reference diagnosis” and analyzed these files with the Tissue of Origin model. Overall agreement with the reference diagnosis was 89%, and an average of 12 tissues could be ruled out with >99% probability. (Pillai et al., 2011). Nystrom et al examined the utility of this test by sending a survey to 65 physicians overseeing 107 patients. They found that, with the gene expression profile results, the diagnosis was changed for 50% of patients and management was changed for 65% of patients (Nystrom et al., 2012).

Clinical Validity and Utility

A number of studies have investigated the validity and diagnostic utility of gene expression profiling in addition to or in place of standard immunohistochemistry in the diagnosis and management of CUP.

Hainsworth et al conducted a prospective trial testing the tumor biopsy specimens from previously untreated patients with CUP with a 92-gene reverse transcriptase polymerase chain reaction cancer classification assay. Molecular tumor profiling correctly identified tissue of origin in 85% of carcinomas of known primary origin. The study showed that molecular tumor profiling predicted a tissue of origin in 247 of 252 (98%) patients with CUP. The authors concluded that “molecular tumor profiling contributes to the management of patients with CUP and should be a part of their standard evaluation (J. D. Hainsworth et al., 2013).”

Greco et al demonstrated that 18 of 24 patients (75%) with latent primaries discovered months to years later were predicted by molecular tumor profiling. The authors concluded that molecular tumor profiling “complements standard pathologic evaluation in determining the tissue of origin in patients with CUP, particularly when IHC is inconclusive (F. A. Greco, Lennington, Spigel, & Hainsworth, 2013).”

Oien and Dennis concluded that “in already well worked-up poorly differentiated and/or metastatic tumours, including CUP, molecular profiling performs well, with sensitivities of 72%–95% and may outperform optimal IHC by 10%–20% (Oien & Dennis, 2012).” The authors conclude that molecular profiling could thus contribute to diagnosis of poorly differentiated and/or metastatic tumors.

Kerr et al. conducted a large multi-institution validation study to examine the performance of a 92-gene molecular cancer classifier. The assay showed overall sensitivities of 87% for tumor type and 82% for subtype. No decrease in comparative performance was observed when metastatic tumors, high-grade tumors or cases with limited tissue were analyzed. The authors concluded that the assay showed strong performance for accurate molecular classification for various tumor histologies. They further state that “results support potential use of the assay as
a standardized molecular adjunct to routine clinicopathologic evaluation for tumor classification and primary site diagnosis (Kerr et al., 2012).”

Handorf et al published the results of a prospectively conducted, blinded, multicenter study that compared the diagnostic accuracy of gene expression profiling (GEP) with IHC in identifying the primary site of metastatic tumors with known primaries. Overall, GEP accurately identified 89% of specimens, compared with 83% accuracy using IHC. In the subset of 33 poorly differentiated and undifferentiated carcinomas, GEP had higher accuracy (91%) compared to IHC (71%). The authors concluded that GEP “was significantly more accurate than IHC when used to identify the primary site of metastatic tumors (Handorf et al., 2013).”

In a similar study design, Weiss et al compared the diagnostic accuracy of IHC analysis versus molecular classification using a 92-gene RT-PCR assay for determination of the primary tumor site. The authors reported 79% accuracy for gene expression profiling compared with 69% for immunohistochemistry. The authors concluded that the results “demonstrate superior accuracy with the 92-gene assay versus standard-of-care IHC analysis and strongly support the diagnostic utility of molecular classification in difficult-to-diagnose metastatic cancer (Weiss et al., 2013).”

Ross et al (2015) conducted comprehensive genomic profiling on 200 CUP formalin-fixed paraffin-embedded specimens (mean, 756× coverage) using the hybrid-capture-based FoundationOne assay for presence of targetable genomic alterations (GAs) in CUP and responses to targeted therapies. They concluded that “Almost all CUP samples harbored at least 1 clinically relevant GA with potential to influence and personalize therapy. The ACUP [adenocarcinomas of unknown primary site] tumors were more frequently driven by GAs in the highly druggable RTK/Ras/mitogen-activated protein kinase (MAPK) signaling pathway than the non-ACUP tumors. Comprehensive genomic profiling can identify novel treatment paradigms to address the limited options and poor prognoses of patients with CUP (Ross et al., 2015).”

Groschel et al investigated if their results from a difficult case could be extrapolated. The authors described an advanced-stage malignancy that mimicked a poorly differentiated soft-tissue sarcoma and did not respond to multiagent chemotherapy. Despite molecular profiling and histopathology analysis, the tissue of origin was not identified. However, the authors believed that immune checkpoint inhibitor therapy was warranted, and several differential diagnoses were theorized, including triple-negative breast cancer (TNBC). The authors assessed 157 TNBC cases from the Cancer Genome Atlas, and found PD-L1 copy number gains (leading to excess PD-L1 mRNA expression) in 24% of cases. The authors concluded that their results “illustrate the impact of multidimensional tumor profiling in cases with nondescript histology and immunophenotype, show the predictive potential of PDL1 amplification for immune checkpoint inhibitors (ICIs), and suggest a targeted therapeutic strategy in Chromosome 9p24.1/PDL1-amplified cancers” (Groschel et al., 2016).

Loffler et al performed next-generation sequencing (of 50 genes) on 55 patients with adenocarcinoma or undifferentiated carcinoma. 46 cases harbored tumor-specific mutations and other alterations. TP53, KRAS, CDKN2A and SMAD4 were the most commonly mutated genes, and 8 cases were identified as having targetable mutations by currently approved drugs. The authors concluded that mutations of relevant driver genes were present in “vast majority” of CUP tumors and that these genes may carry impact on prognosis and targeted therapy (Loffler et al., 2016).

Santos et al (2017) aimed to develop and validate a gene-expression classifier to identify potential primary sites for metastatic cancers more accurately. “The gene-expression classifier correctly identified, by a cross-validation, 86.6% of the expected cancer superclasses of 4429 samples from the RefDB, with a specificity of 99.43%. Next, the performance of the algorithm for classifying the validation set of metastatic FFPE samples was 83.81%, with 99.04% specificity. The overall reproducibility of our gene-expression-classifier system was 97.22% of precision, with a coefficient of variation for inter-assays and intra-assays and intra-lots <4.1% (Santos et al., 2017).”
Zehir et al attempted to characterize the mutational landscape of metastatic cancer. 10945 tumor samples from 10336 patients were included. Tumors were sequenced with 2 panels, one of 341 genes, and another of 410 genes (with all 341 genes from the former panel included). Tumors were sequenced to an average of 718x coverage. Non-small cell lung cancer was the most common, with 1563 patients, followed by breast carcinoma at 1237 patients and colorectal cancer at 978 patients. Cancers of unknown primary comprised of a total of 160 patients. Overall, the authors identified 36.7% of patients as having actionable mutations (n = 3792). Gastrointestinal stromal tumors (76%), thyroid cancer (60%) and breast cancer (57%) were found to have the highest proportion of actionable mutations. However, the highest standard of actionable mutation met for cancers of unknown primary was "level 2B", or "standard of care biomarker for an FDA-approved drug in another indication". The authors concluded that their data "demonstrate[d] the feasibility and utility of large-scale prospective clinical sequencing of matched tumor-normal pairs to guide clinical management (Zehir et al., 2017).

Varghese et al aimed to provide a “clinical and pathologic” description of patients with cancers of unknown primary. 150 patients had targeted next-generation sequencing performed. 45 patients were identified to have “potentially actionable” mutations, and 15 patients received targeted therapies. The authors remarked that CUP patients may benefit from targeted therapies (Varghese et al., 2017).

Gatalica et al attempted to identify predictive biomarkers for immune checkpoint blockade therapy in cancers of unknown primary (CUP). 389 cases were analyzed for 592 mutations and 52 gene fusions through next-generation sequencing. Microsatellite instability (MSI), total mutational load (TML), and PD-L1 expression were all evaluated. The authors identified “high” TML in 11.8% of tumors, high MSI in 7 tumors, and PD-L1 expression in 80 (of 362 tested cases) tumors. Other predictive biomarkers such as MDM2 gene amplification were identified. TP53 gene mutations were found in 54% of cases, followed by KRAS (22%) and ARID1A (13%). Overall, the authors identified 28% of CUP cases as carrying a predictive biomarker for immune checkpoint blockade therapy (Gatalica, Xiu, Swensen, & Vranic, 2018).

Clynick et al attempted to identify actionable mutations in cancers of unknown primary. 21 cases were included, and two gene panels were used to evaluate variants in 76 cancer-related genes. The authors found variants in 17 of 21 cases, with 11 considered “potentially actionable”. The most common variants detected were TP53 (47%), KRAS (12%), MET (12%) and MYC (12%). The authors also remarked that CUP adenocarcinomas and poorly differentiated carcinomas tended to harbor gene mutations involved in signal transduction pathways (8 of 11 cases harboring mutations such as BRAF, HRAS, and KRAS), whereas squamous cell carcinomas tended to harbor mutations in genes involved in cell cycle control and DNA repair genes (all 8 cases harboring mutations such as TP53, MLH1, and CDKN2A). Overall, the authors identified mutations in “biologically relevant” genes in the “vast majority” of CUP tumors, noting that half provided a “potentially novel treatment not generally considered in CUP” (Clynick et al., 2018).

Hayashi et al compared two treatments for cancers of unknown primary site. Empirical chemotherapy was compared against site-directed therapy (directed by comprehensive microarray-based gene expression profiling). Efficacy analysis was performed for 50 patients in the site-specific arm and 51 patients in the empirical chemotherapy arm. 1-year survival rate was found to be 44% for site-specific treatment and 54.9% for empirical treatment (p = .264). Median overall and progression-free survival was found to be 9.8 months and 5.1 months respectively for site-specific treatment and 12.5 months and 4.8 months respectively for empirical treatment (p=.896 and .550, respectively). Overall, the authors concluded that “Site-specific treatment that was based on microarray profiling did not result in a significant improvement in 1-year survival compared with empirical PC [treatment]” (Hayashi et al., 2019).

Fizazi et al evaluated the utility of “tailored treatment” for cancers of unknown primary. 243 patients with cancers of unknown primary were included, and were randomized to Arm A
(“Cisplatin 100 mg/m2 d1p Gemcitabine 1250 mg/m2 , day 1 and 8, q3w”, empiric treatment) or Arm B (“gene expression test followed by a la carte treatment according to the suspected primary”, tailored). The gene expression tests used were Pathwork’s Tissue of Origin (n = 21) or CancerTYPE (n = 222), and the primary endpoint was defined as progression-free survival at a hazard ratio of 0.625. The four most common tissues of origin were “pancreatico-biliary cancer (19%), squamous cell carcinoma (11%, kidney cancer (8%) and lung cancer (8%)”. 91 of the 123 patients in Arm B were given tailored treatment. Progression-free survival in both arms were similar (both by central and local review), overall survival was similar in both arms (hazard ratio = 0.92). Overall, the authors concluded that “using a molecular test followed by tailored systemic treatment did not improve outcomes of pts [patients] with CUP” (Fizazi et al., 2019).

Guidelines and Recommendations

National Comprehensive Cancer Network (NCCN) (NCCN, 2020)

The NCCN lists two primary applications of molecular profiling in management of CUP; using gene expression profiling to determine tissue of origin for site-specific therapy, and identifying actionable mutations for targeted therapy (NCCN, 2020).

The 2020 National Comprehensive Cancer Network guidelines for the workup of an occult primary malignancy address the use of molecular methods in the classification of tumors. The guidelines state “Tumor sequencing and gene signature profiling for tissue of origin is not recommended for standard management at this time.” A footnote acknowledges that “there may be diagnostic benefit, though not necessarily clinical benefit. The use of gene signature profiling is a category 3 recommendation” The guidelines further recommend that “until more robust outcomes and comparative effectiveness data are available, pathologists and oncologists must collaborate on the judicious use of these modalities on a case-by-case basis, with the best possible individualized patient outcome in mind (NCCN, 2020).”

Overall, the NCCN states that “the clinical benefit that might be derived from the use of GEP [gene expression profiling] assays, if any, remains to be determined.” The NCCN also states that “currently, there is no evidence of improved outcomes with the use of site-specific therapy guided by molecular testing results in CUP patients” (NCCN, 2020).

National Institute for Health and Clinical Excellence (NICE) (NICE, 2010)

A 2010 clinical guideline from NICE, which was reaffirmed in 2017, recommended against the use of gene expression-based profiling to identify primary tumors in patients with CUPs. The guideline also states, “do not use gene-expression-based profiling when deciding which treatment to offer patients with confirmed CUP (NICE, 2010).”

European Society of Medical Oncology (ESMO) (Fizazi et al., 2015)

In 2015, ESMO stated that several gene expression profiling assays for cancers of unknown primary have become commercially available, but “their impact on patient outcome via administration of primary site specific therapy remains questionable and unproven in randomised trials” (Fizazi et al., 2015).

National Cancer Institute (NCI, 2018)

The NCI acknowledges the possible utility of gene expression profiling to discover the origin site of unknown cancers. However, they also note that this method has not been validated against the gold standard and requires further study (NCI, 2018).
**State and Federal Regulations, as applicable**

No FDA-approved tests for the assessment of cancer from an unknown primary site were found. Additionally, many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88). As an LDT, the U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use.

**Applicable CPT/HCPCS Procedure Codes**

<table>
<thead>
<tr>
<th>Code Number</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
<tr>
<td>81504</td>
<td>Oncology (tissue of origin), microarray gene expression profiling of &gt; 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores</td>
</tr>
<tr>
<td>81540</td>
<td>Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype</td>
</tr>
<tr>
<td>81599</td>
<td>Unlisted multianalyte assay with algorithmic analysis</td>
</tr>
</tbody>
</table>


*Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.*

**Evidence-based Scientific References**


Policy Implementation/Update Information

1/1/20  New Policy
8/1/20  Literature review required the following modification to the coverage criteria: the title was changed to “Molecular Profiling for Cancers of Unknown Primary Origin to better describe the policy.” Further, CC1 and CC2 were updated based on NCCN v.2. 2020 guidelines.

State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health
care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.